{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:08:35Z","timestamp":1778065715667,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jdiacomp.2023.108632","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:27:12Z","timestamp":1697848032000},"page":"108632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"37","author":[{"given":"Mengnan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi'ang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108632_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0010","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/193229681100500419","article-title":"Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials","volume":"5","author":"Gandhi","year":"2011","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00125-019-05027-0","article-title":"Positioning time in range in diabetes management","volume":"63","author":"Advani","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13098-021-00654-3","article-title":"A review of flash glucose monitoring in type 2 diabetes","volume":"13","author":"Krakauer","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0035","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.295.14.1681","article-title":"Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes","volume":"295","author":"Monnier","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12933-015-0275-3","article-title":"Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes","volume":"14","author":"Okada","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0045","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/db12-1396","article-title":"Glucose variability","volume":"62","author":"Service","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12933-018-0677-0","article-title":"Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study","volume":"17","author":"Cardoso","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0055","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/dc14-0199","article-title":"Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial","volume":"37","author":"Hirakawa","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-020-01085-6","article-title":"Glycemic variability: adverse clinical outcomes and how to improve it?","volume":"19","author":"Zhou","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12933-019-0975-1","article-title":"Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort","volume":"18","author":"Slieker","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12933-018-0761-5","article-title":"Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome","volume":"17","author":"Takahashi","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12020-019-01893-1","article-title":"Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes","volume":"64","author":"Sun","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0080","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0085","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrendo.2017.139","article-title":"Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk","volume":"13","author":"Ferrannini","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S2213-8587(16)00039-5","article-title":"Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus","volume":"4","author":"Frandsen","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0095","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0100","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMe1711296","article-title":"Adjunctive treatments for type 1 diabetes","volume":"377","author":"Nathan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0110","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/1753-0407.12890","article-title":"Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Li","year":"2019","journal-title":"J Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l1328","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials","author":"Musso","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0135","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0145","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/pedi.12698","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: assessment and management of hypoglycemia in children and adolescents with diabetes","volume":"19 Suppl 27","author":"Abraham","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0160","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","article-title":"Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Yamada","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0165","author":"AstraZeneca"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0170","author":"AstraZeneca"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0175","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/dom.14144","article-title":"Benefit\/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index \u226527 kg\/m2","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0180","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/dom.14258","article-title":"Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study","volume":"23","author":"Biester","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejogrb.2021.12.011","article-title":"Diabetic ketoacidosis in pregnancy - case series, pathophysiology, and review of the literature","volume":"269","author":"Eshkoli","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0195","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA(1c) and hypoglycemia reductions at 24 and 52 weeks with Sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0200","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/dc18-2149","article-title":"Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the IntanDEM program","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0205","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0210","author":"Nct"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0215","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0220","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2337\/dc18-1983","article-title":"Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2","volume":"42","author":"Mathieu","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0230","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41591-022-01805-3","article-title":"Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 \u00d7 2 factorial randomized crossover trial","volume":"28","author":"Haidar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0235","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/dia.2021.0542","article-title":"Automated insulin delivery with SGLT2i combination therapy in type 1 diabetes","volume":"24","author":"Garcia-Tirado","year":"2022","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0240","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/dia.2016.0261","article-title":"Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"19","author":"Famulla","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0250","author":"Nct"},{"key":"10.1016\/j.jdiacomp.2023.108632_bb0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes","volume":"40","author":"Rodbard","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723002301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:17:32Z","timestamp":1761005852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723002301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1056872723002301"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108632","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023","name":"copyright","label":"Copyright"}],"article-number":"108632"}}